Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for You?

If you've been researching medical weight loss, you've likely encountered two names more than any others: semaglutide and tirzepatide. Sold under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, these medications have transformed the treatment of obesity and become among the most searched health topics of 2025 and 2026.

But which one is right for you? And how do you decide? At JS wellness in Eudora, KS, we prescribe both — and we make the recommendation based on your individual health profile, labs, and goals. Here's what you need to understand about both medications before you start.

How GLP-1 Medications Work

GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces after eating. It signals the brain that you're full, slows gastric emptying so food moves through your digestive system more gradually, and helps regulate blood sugar.

In people who struggle with obesity or weight-related metabolic conditions, this signaling is often blunted or insufficient. GLP-1 receptor agonists mimic and amplify this natural hormone — giving the body the clear, sustained satiety signal it was missing.

The result: reduced appetite, fewer cravings, feeling full on smaller portions, and improved blood sugar regulation. Together, these effects make it possible to achieve significant, sustained weight loss that is simply not achievable through diet and willpower alone for many people.

Semaglutide: The Proven Standard

Semaglutide is a GLP-1 receptor agonist — meaning it targets the GLP-1 receptor specifically. It was originally developed for type 2 diabetes management (Ozempic) and later approved at a higher dose specifically for weight management (Wegovy).

How It's Used

Semaglutide is administered as a weekly subcutaneous injection. The dose is escalated gradually over several months to minimize side effects and allow the body to adapt. At JS wellness, we use compounded semaglutide sourced from licensed compounding FDA monitored pharmacies, which allows for precise, individualized dosing tailored to your response.

What the Research Shows

In clinical trials, semaglutide at the full 2.4 mg weight management dose produced an average weight loss of approximately 13–15% of body weight over 68 weeks. In real-world settings, a 2025 study found average weight loss of about 7.7% at one year — reflecting lower doses and the real-world adherence challenges that clinical trials don't fully capture. Patients who reached higher doses and maintained consistent treatment achieved results much closer to trial outcomes.

Semaglutide has also demonstrated a 20% reduction in major cardiovascular events in patients with obesity and established cardiovascular disease — making it uniquely valuable for patients with heart health concerns.

Tirzepatide: The Newer, More Powerful Option

Tirzepatide is a dual GIP/GLP-1 receptor agonist — meaning it activates two receptors instead of one. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that works synergistically with GLP-1 to regulate appetite, insulin, and fat metabolism. This dual mechanism is why tirzepatide consistently outperforms semaglutide in head-to-head comparisons.

How It's Used

Like semaglutide, tirzepatide is a weekly subcutaneous injection with a gradual dose escalation schedule. It is available as Zepbound (FDA-approved for weight management) and Mounjaro (FDA-approved for type 2 diabetes). At JS wellness, we offer compounded tirzepatide for individualized dosing when appropriate.

What the Research Shows

In the landmark SURMOUNT-5 trial — the first direct head-to-head comparison of tirzepatide and semaglutide — tirzepatide produced approximately 20% weight loss compared to 14% with semaglutide over 72 weeks. Some tirzepatide trials have reported average weight loss of up to 22.5% of body weight at maximum doses. In real-world data from 2025, patients on tirzepatide lost an average of 12.4% of body weight at one year — significantly more than the 7.7% seen with semaglutide in the same analysis.

Tirzepatide has also received FDA approval for obstructive sleep apnea — making it the first medication approved for this condition — reflecting its broad metabolic impact beyond weight loss alone.

The clinical data is clear: tirzepatide produces greater average weight loss than semaglutide. But 'better on average' doesn't mean 'better for everyone.' Individual response varies, and the right medication is always the one that works for your specific body and health profile.

Semaglutide vs. Tirzepatide: Side by Side

Effectiveness

Tirzepatide has demonstrated superior average weight loss in both clinical trials and real-world data. For patients who need to lose a significant amount of weight or whose metabolism has been resistant to other approaches, tirzepatide is often the stronger first choice.

Side Effects

Both medications share similar side effect profiles — primarily gastrointestinal: nausea, constipation, mild diarrhea, and occasionally fatigue, particularly during dose escalation. These side effects are dose-dependent and typically improve as the body adapts. A slow, gradual titration approach — which we use at JS wellness — significantly reduces their frequency and severity.

Cardiovascular Benefits

Semaglutide currently has the stronger cardiovascular outcomes data, with robust evidence of reduced heart attack and stroke risk in high-risk patients. Tirzepatide's cardiovascular trial data is emerging and promising but not yet as extensive.

Who Each Is Best For

Semaglutide may be the better starting choice for patients with established cardiovascular disease, those who prefer to start with a well-established medication with longer safety history, or patients for whom tirzepatide is not appropriate due to health history.

Tirzepatide is often the preferred choice for patients who need more substantial weight loss, those with insulin resistance or type 2 diabetes, patients who have had limited results with other weight loss approaches, or anyone for whom maximum metabolic impact is the priority.

Why Medical Supervision Matters

Both medications are highly effective — and both require careful, individualized management to achieve the best outcomes. At JS wellness, every GLP-1 program begins with comprehensive lab work, a full health history review, and a body composition assessment. We recommend the right medication for your specific situation, start at a conservative dose, and monitor your progress monthly.

We also address the lifestyle components that determine whether your results are lasting: protein optimization, strength training, sleep, and — when relevant — hormone optimization that creates the right internal environment for your weight loss efforts to succeed.

The difference between a successful GLP-1 program and a disappointing one often comes down to the quality of the medical supervision surrounding it — not just the medication itself.

Ready to start your weight loss journey? JS Wellness | 913-398-1623 | jswellnessks.com | 715 Main St, Eudora, KS | Mon–Thurs 9–5 | Book at jswellness.janeapp.com

Serving patients from Eudora, Lawrence, Tonganoxie, De Soto, Linwood, Basehor, and the greater Kansas City metro area.